Clinical efficacy of valsartan combined with the forefront of alprostadil in treatment of diabetic nephropathy
- VernacularTitle:缬沙坦联合前列地尔治疗糖尿病肾病的临床疗效观察
- Author:
Jianjing ZHANG
1
;
Jing SUN
Author Information
1. 浙江省岱山县第一人民医院内科
- Keywords:
Diabetic nephropathy;
Valsartan;
Alprostadil
- From:
China Modern Doctor
2015;(11):32-34,38
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy of valsartan combined with alprostadil in treatment of diabetic nephropathy. Methods Selected 84 cases of diabetic nephropathy patients in our hospital from January 2010 to January 2014. According to the different treatment methods they were divided into observation group and control group, each of 42 cases, two groups were treated with high quality low protein diabetic diet, and received the hypoglycemic (insulin), symptomatic treatment, anticoagulant buck. The control group was treated with alprostadil injection 10 μg with 20 mL of physiological saline bolus, once a day, for 12 weeks. On the basis of control group, the observation group was given valsartan 80 mg, 2 times daily, orally, 4 weeks for a course of treatment for 12 weeks. The changes of 24 hours urinary protein, creatinine, urea nitrogen before and after treatment and the effects of two groups after treatment were com-pared. Results The 24 hours urine protein, Cr, BUN levels before treatment had no significant difference between two groups of patients (P>0.05). After treatment, two groups of patients with Cr, BUN levels had no obvious changes with those before therapy, but of 24 hour urinary protein quantitative the observation group significantly decreased than be-fore treatment and control group after treatment, there was statistically significant difference between two groups (P<0.05). After treatment, the observation group's efficiency was 90.5%, control group was 73.8%, observation group's effi-ciency was significantly higher than the control group, there was significant difference between two groups (P<0.05). Throughout the course of treatment, the control group one case of transient palpitations, three cases of dizziness and headache, one case of cough. In the observation group two cases of cough, two cases of dizziness and headache, which were mild severity and did not affect the continued treatment. Conclusion The therapeutic effect of valsartan com-bined with alprostadil in treatment of diabetic nephropathy is accurate, can significantly improve renal function, is wor-thy of promotion and application.
